Acquired BRAFi Resistance Increases Melanoma Cell Sensitivity to Metabolic Targeting with Metformin. (PubMed, Int J Mol Sci) - Sep 27, 2026 - "This study aimed to investigate the molecular, phenotypic, and metabolic adaptations underlying acquired resistance to the BRAFi GSK2118436 in A375 melanoma cells. Importantly, while simultaneous BRAFi-metformin combination caused mostly antagonist effects, a sequential regimen (BRAFi followed by metformin) elicited additive/synergistic cytotoxicity in both 2D and 3D models. Collectively, these findings show that BRAFi resistance is driven by coordinated EMT and metabolic rewiring toward OXPHOS dependency and suggest that sequential metabolic targeting is an effective strategy to overcome therapy resistance in melanoma."
Journal • Melanoma • Oncology • Solid Tumor • CDH1 • VIM
|
|
Gerardo Claudio Glikin; Liliana María Elena Finocchiaro; Marcela Solange Villaverde; María Florencia Arbe
|